Cytovale to present new data on rapid sepsis test at AACC

By staff writers
July 25, 2022

Cytovale said Monday that it will present new data at AACC 2022 about its 10-minute IntelliSep test for sepsis and its associated system.

The firm noted it has already submitted an application to the U.S. Food and Drug Administration for clearance of the system and test, which aims to help emergency departments rapidly and more effectively triage patients.

Emergency department physicians tasked with diagnosing sepsis, a dysregulated immune response to infection that can be life-threatening, often face a scarcity of information that could lead to over- or undertreatment.

To help address this challenge, the Cytovale system directly analyzes white blood cells using rapid techniques that look at cell structure, which may make it faster and less expensive than other approaches, the firm said.

Cytovale said that the IntelliSep test was recently named an AACC Disruptive Technology Award semifinalist and is also being featured in the Disruptive Tech area of the exhibit hall during the meeting.

Bluejay Diagnostics completes clinical studies for sepsis triage
Bluejay Diagnostics on Wednesday announced the completion of clinical studies for its Symphony IL-6 Test for sepsis triage.
Nanomix launches trial of eLab analyzer and panel
Nanomix has launched a trial in Spain to evaluate its eLab mobile immunoassay diagnostic system and S1 Panel assay for the detection of critical infections.
Immunexpress sepsis test gets FDA 510(k) clearance
Immunexpress' SeptiCyte Rapid fully automated diagnostic tool has been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA). The...
Cytovale tests sepsis diagnostic in COVID-19 patients
Medical cell technology company Cytovale is set to conduct a pilot study of its rapid diagnostic test for sepsis in patients with suspected SARS-CoV-2...

Copyright © 2022

Last Updated 7/25/2022 1:06:34 PM